15 results about "Refractory epilepsy" patented technology

Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein Ring A, Ring B, R1, R2, R3, R12, and L are as defined herein. The compounds are antagonists of the resistant (R-type) voltage-gated calcium ion channel Cav 2.3. Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in the treatment of diseases modulated Cav 2.3, including epilepsy, neurodegenerative conditions such as Parkinson's disease, focal, drug-resistant forms of epilepsy, and other neurological disorders such as developmental and epileptic encephalopathies and Phelan-McDermid and Fragile X syndromes.

The application discloses an online self-adaptive seizure prediction method and system, relates to the technical field of medical signal processing and artificial intelligence, and comprises the following steps: acquiring multi-channel electroencephalogram signals of a target user; constructing an online self-adaptive seizure prediction model according to spatially constrained independent component analysis, brain function network and a transfer learning mechanism; inputting the multi-channel electroencephalogram signals into the online self-adaptive seizure prediction model, identifying and predicting a pre-seizure state, and obtaining a prediction result; and performing online early warning judgment according to the prediction result, and triggering an alarm if early warning conditions are met. The application solves the problem of unstable early warning effect caused by the variability of electroencephalogram data of epilepsy, realizes online seizure prediction with clinical accuracy and rapidness, and provides a basis for the treatment of intractable epilepsy and the research on the seizure mechanism of epilepsy.

The invention belongs to the technical field of medicines, and discloses application of asarinol and derivatives thereof in treatment of the Dravet syndrome. The structural general formula of asarinol and the derivatives thereof is shown in (I). Researches find that in an scn1lab / zebra fish model, alpha-asarone, beta-asarone and derivatives thereof can reduce epilepsy-like discharge by 23%-93%, and the effect is obviously superior to that of stiripentanol and cannabidiol. Related pharmaceutical preparations can be prepared into capsules, dry suspensions or gels and the like, the dry suspensions are more suitable for children to take, and the capsules and the gels are suitable for adults to take. In addition, toxicological studies show that the compound is high in safety and free of remarkable developmental toxicity. The invention provides a safe and efficient novel treatment scheme for the Dravot syndrome and intractable epilepsy, and has important clinical transformation value. (I)

Systems, devices, and methods for treating drug-refractory epilepsy are disclosed. [Solution] In one embodiment, a method for treating epilepsy is disclosed, comprising detecting electrophysiological signals of a subject using a first electrode array coupled to a first intravascular carrier. The method further comprises analyzing the electrophysiological signals using a neuromodulator electrically coupled to the first electrode array, and stimulating a target site in the subject's body using a second electrode array coupled to a second intravascular carrier implanted in a portion of a body blood vessel above the base of the subject's skull.

The invention relates to a gene therapy vector for treating drug-refractory epilepsy and application of the gene therapy vector. Specifically, based on the new discovery that the expression level of A1R is obviously reduced in ANT brain region excitatory neurons of a chronic spontaneous epilepsy mouse model, the invention constructs a recombinant adeno-associated virus vector AAV2 / 9-CamKIIA-A1R-P2A-GFP on the basis of a pAV-CamKIIA-P2A-GFP vector for the first time. Wherein the CamKIIA promoter is only activated in excitatory neurons, so that the specific expression of a target gene is ensured; the P2A self-cleaving peptide sequence ensures the independence of respective functions of the target gene and the reporter gene. The vector has the advantages of high specificity, visual expression efficiency, safety, reliability, optimized packaging capacity and the like. A gene therapy scheme based on the vector has the technical advantages of strong targeting, low invasiveness, lasting treatment effect, clear mechanism, high safety and the like.

The application provides a brain cortex thickness morphological analysis method and system of MR images, and relates to the technical field of medical image data processing.The method comprises the following steps: obtaining a head three-dimensional high-resolution magnetic resonance T1 weighted image sequence of a patient with intractable epilepsy to be evaluated; performing bias field correction and brain tissue stripping on the image sequence to construct an initial brain parenchyma three-dimensional voxel model containing individual lateral ventricle expansion morphological characteristics; based on the initial brain parenchyma three-dimensional voxel model, extracting an initial isosurface of the interface between gray matter and white matter; calculating a local curvature tensor for a deep brain sulcus region in the initial isosurface; performing topological defect repair and mesh smoothing on the initial isosurface according to the local curvature tensor to obtain an individualized cortex surface mesh model eliminating ventricle expansion deformation artifacts.The application realizes accurate registration of image space and surgical physical space.

The invention belongs to the technical field of medicines, and particularly relates to an aryl alkyl azole derivative as well as a preparation method and application thereof. Benzo [d] [1, 3] thiazine is used as aryl and is directly connected with 4H-1, 2, 4-triazole-4-yl through a chemical bond, and alkoxy is introduced to the C6 position of the aryl, so that the aryl alkyl azole derivative is obtained. The compound disclosed by the invention is novel in structure, shows excellent anti-convulsion activity in two epilepsy models of maximum electroshock and subcutaneous pentyltetrazole as a GABAA receptor agonist, and particularly shows an extremely high protection index, PIgt, in the subcutaneous pentyltetrazole model; and 10, the compound has the remarkable advantages of various action mechanisms, wide therapeutic window and low neurotoxicity, can be used for preparing the anti-epilepsy medicine, and is particularly suitable for treating intractable epilepsy.

The invention provides a neural stem cell induced differentiation and clinical application method for intractable epilepsy, and relates to the technical field of biological medicine, the induced differentiation method comprises the following steps: S1, cell source and preparation: adopting induced pluripotent stem cells from a patient; s2, constructing an induced differentiation system, differentiating the induced pluripotent stem cells into GABA (gamma-aminobutyric acid) inhibitory interneurons, and differentiating the GABA inhibitory interneurons; s3, purifying and amplifying the cells, adopting immunomagnetic bead sorting, and purifying and enriching the cells expressing the GABA energy neuron marker; s4, cell quality control; according to the method, the autologous induced pluripotent stem cells of the patient are taken as a source, immunological rejection is avoided, the transplanting safety is improved, and moreover, the high-purity GABAergic neurons can more effectively supplement damaged inhibitory neurons in the brain of the epileptic and reconstruct the inhibition balance of a neural network, so that the epileptic seizure is more effectively controlled.

The invention discloses an online adaptive prediction method and system for epileptic seizure, and relates to the technical field of medical signal processing and artificial intelligence, and the method comprises the steps: obtaining a multi-channel electroencephalogram signal of a target user; constructing an epileptic seizure online adaptive prediction model according to spatial constraint independent component analysis, a brain function network and a transfer learning mechanism; inputting the multi-channel electroencephalogram signals into an online adaptive epileptic seizure prediction model, and performing state identification and prediction before epileptic seizure to obtain a prediction result; and performing online early warning judgment according to a prediction result, and triggering an alarm if an early warning condition is met. According to the method, the problem of unstable early warning effect caused by epilepsy electroencephalogram data variability is solved, clinical accurate and rapid online epileptic seizure prediction is realized, and a basis is provided for treatment of refractory epilepsy and research on a seizure mechanism of the refractory epilepsy.

The present application relates to the technical field of gene detection, in particular to a gene panel, method, device and use for somatic cell variation detection of SLC35A2 gene. The present application provides a gene panel, which can target capture the entire SLC35A2 gene related region, including exons, introns, promoters and enhancers, and carry out somatic cell variation detection, including SNVs, small Indels and SVs. The panel is used for detection of refractory epilepsy surgical brain tissue specimens, and can genetically diagnose mild cortical dysplasia with oligodendrogliosis epilepsy (MOGHE). This kind of disease is a new subtype of focal cortical dysplasia newly included by the International League Against Epilepsy in 2022. The panel has high variation detection rate and more comprehensive variation detection types.

The application discloses a brain network analysis method based on step-by-step information flow and de-redundancy, and belongs to the field of image analysis; solves the problems that a simple network building mode cannot reflect the information flow propagation process between specific regions at different levels, and information redundancy caused by the repeated existence of some edges in different high-order adjacency matrices, etc. The interaction between electrodes at the connection level is mainly captured through a step-by-step process, and the redundant information between matrices of different orders is eliminated by using a de-redundancy module. Finally, the epilepsy propagation path is successfully captured, thereby providing a reference value for surgical resection of intractable epilepsy patients.

The present invention relates to the field of epilepsy, and more specifically, discloses a clinical system for closure surgery in patients with refractory epilepsy accompanied by high shunt flow PFOs. The system comprises a patient medical record information acquisition and storage module for acquiring and storing electronic medical record data of epilepsy patients, wherein the types of electronic medical record data include sex, age at surgery, age of epilepsy onset, seizure frequency, normality of 24-hour EEG examination, and seizure duration, and the electronic medical record data includes sample data from a sample population and subject data from a subject; a patient selection module for selecting subjects who may be suitable for PFO closure surgery; and a preoperative efficacy evaluation module for evaluating the effectiveness of the subject if they undergo the PFO closure surgery. The clinical system provided by the present invention has a complete and normative evaluation system for patient selection and exclusion, and is useful for guiding the selection, decision-making, and postoperative management of epilepsy patients suitable for application of PFO closure surgery.

Systems, apparatus, and methods for treating medication refractory epilepsy are disclosed. In one embodiment, a method of treating epilepsy is disclosed comprising detecting, using a first electrode array coupled to a first endovascular carrier, an electrophysiological signal of a subject. The method further comprises analyzing the electrophysiological signal using a neuromodulation unit electrically coupled to the first electrode array and stimulating an intracorporeal target of the subject using a second electrode array coupled to a second endovascular carrier implanted within a part of a bodily vessel superior to a base of the skull of the subject.

The invention is suitable for the technical field of refractory epilepsy prediction, and provides an RE prediction method and system based on a conditional generative adversarial neural network and a column diagram, and the method comprises the following steps: obtaining data, and carrying out the preprocessing; constructing a CGAN model, and enhancing the data; performing multi-factor Logistic regression risk factor screening on the enhanced data; and constructing a column graph model for prediction. According to the embodiment of the invention, the data is input through the CGAN model for data enhancement, comprehensive information is provided for subsequent analysis, the data enhanced by the CGAN is combined, multi-factor binary Logistic regression analysis is adopted, independent risk factors are screened out, OR values of the factors are quantified, and the influence degree is determined; and constructing a column graph prediction model to ensure the precision and generalization ability of the model.

The application belongs to the technical field of medicine, and particularly relates to an arylalkyl azole derivative, a preparation method and application thereof. The arylalkyl azole derivative is obtained by directly connecting 4H-1,2,4-triazole-4-yl to benz[d][1,3]thiazine as aryl through a chemical bond and introducing an alkoxy group at the C6 position of the aryl. The compound of the application has a novel structure, and as a GABA_A receptor agonist, exhibits excellent anticonvulsant activity in two kinds of epilepsy models of maximum electric shock and subcutaneous pentylenetetrazole. In particular, the compound exhibits an extremely high protection index PI>10 in the subcutaneous pentylenetetrazole model, indicating that the compound has the remarkable advantages of diverse action mechanism, wide therapeutic window and low neurotoxicity, and can be used for preparing an antiepileptic drug, and is particularly suitable for the treatment of refractory epilepsy.